Organoids Market to Reach USD 381.7 Million by 2034, Expanding at a Robust 18.5% CAGR | Reports Towards Healthcare

GlobeNewswire On November 3, 2025 18:30 IST

The global organoids market size is calculated at USD 82.80 million in 2025 and is expected to reach around USD 381.7 million by 2034, growing at a CAGR of 18.5% for the forecasted period.

Ottawa, Nov. 03, 2025 (GLOBE NEWSWIRE) — The global organoids market size was valued at USD 69.90 million in 2024 and is predicted to hit around USD 381.7 million by 2034, rising at a 18.5% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Key Takeaways

North America held a dominant revenue share of the market in 2024.
Asia Pacific is expected to grow at a rapid CAGR in the coming years.
By type, the stem cell source segment led the organoids market in 2024.
By type, the tumour cell source segment is expected to witness rapid expansion during 2025-2034.
By application type, the pharmaceutical R&D segment registered dominance in the market in 2024.
By application type, the precision medicine segment is expected to be the fastest-growing in the studied years.

Focus on Complex Creations: What are the Transforming Factors of Organoids?

Basically, the organoids market encompasses miniature, lab-grown organs developed from stem cells that mimic the structure and function of full-sized organs. Growth factors involved in this expansion are the growing demand for tailored medicine, drug discovery, and regenerative therapies. Whereas, current developments by researchers are emphasising creating more complex models, such as organoids for nearly the complete human body, like the brain, oesophagus, stomach, and intestines. Alongside, they have established Biobots, which are smaller, mobile biological robots with cilia.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5265

What are the Vital Drivers in the Organoids Market?

The market is propelled by ongoing faster developments in the generation of organoids from induced pluripotent and embryonic stem cells, which allows the evolution of highly advanced and functional mini-organs. Alongside, these well-developed organoids offer precise models in the study of the pathogenesis of complex chronic diseases, specifically cancer, diabetes, and neurodegenerative disorders, which is significant for understanding disease mechanisms. Organoids also foster the identification of drug toxicity early, lowering expenditures connected with late-stage drug failure.

What are the Key Drifts in the Organoids Market?

In October 2025, Merck, a major science and technology company, collaborated with Promega Corporation to co-develop novel technologies that advance drug screening and discovery, also integrating Merck’s strength in organoids and synthetic chemistry with Promega’s market.
In July 2025, Korean preclinical CRO CorestemChemon partnered with ATG Lifetech to accelerate the development of organoids and transcriptomics.
In June 2025, Parallel Bio, a biotech company, secured $21 million in Series A funding to advance human-first drug discovery.

What is the Significant Challenge in the Organoids Market?

A rise in the need for greater expenses, mainly for reagents and infrastructure, as well as being coupled with technical concerns, like acquiring vascularization and consistent quality control, is creating hurdles in the ultimate market expansion.

Regional Analysis

Why did North America Dominate the Market in 2024?

North America accounted for the biggest share of the market in 2024. The regional growth is fueled by the increasing major investments in biotechnology and life sciences from both the government and private sectors, and the widespread application of organoids in drug discovery and precision medicine. Also, certain researchers are leveraging the integration of organoids with microfluidic chips (organ-on-a-chip technology), which enables robust control of the cellular environment and the modelling of complex, multi-organ interactions.

For instance,

In September 2025, the National Institutes of Health (NIH) established the Standardized Organoid Modeling (SOM) Center to evolve standardized organoid-based new approach methodologies (NAMs) & minimal dependence on animal modeling.

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

How did the Asia Pacific Grow Significantly in the Market in 2024?

Asia Pacific is anticipated to register the fastest growth during 2025-2034 in the organoids market. ASAP is increasingly promoting the progression of the healthcare and biotechnology sectors, with raised government support for initiatives, such as stem cell and precision medicine research. Recently, China has established an on-chip brain-computer interface system using cultured brain organoids. Whereas India is encouraging alliances for optimizing access to advanced 3D cell culturing platforms for researchers.

For instance,

In July 2025, Hong Kong-based Centre for Immunology & Infection Limited (C2i) and Japanese multinational conglomerate Hitachi collaborated for the development of 3D printed airway organoids for clinical applications.

Organoids Market: Latest Initiatives in 2024-2025

California Institute for Regenerative Medicine (CIRM)	In October 2025, Scripps Research received a $4 million grant from CIRM for the application of cortical organoids to study the possible gene therapies for severe epilepsy.
NSW Organoid Innovation Centre (NSWOIC)	It was developed in 2025 to facilitate researchers ‘ access to stem cell and organoid cultures.
Organoid Symposium and Funding	In 2024, the government-funded Stem Cell Network co-hosted the 2024 Organoid Symposium with the University of Toronto’s Applied Organoid Core.
Organoid Intelligence (OI) Program	In 2024, the National Science Foundation (NSF) invested $14 million in a program for the transformation of “Organoid Intelligence.”

Segmental Insights

Which Type Led the Organoids Market in 2024?

The stem cell source segment held a major revenue share of the market in 2024. Prominently, pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) and adult stem cells (ASCs), are widely used. They have broader significances in disease modeling and drug discovery for patient-specific applications, specifically for neurodegenerative and gastrointestinal diseases. Also, players are supporting the use of microfluidics, bioreactors, and 3D bioprinting for the creation of more physiologically relevant organoids.

On the other hand, the tumour cell source segment is estimated to expand rapidly in the coming era. The emergence of patient-derived tumour organoids (PDTOs) explores their importance in personalized medicine, high-throughput drug screening, and estimating patient responses to specific treatments. Furthermore, researchers are implementing the application of circulating tumour cells and biopsies from bodily fluids, as well as more sophisticated genetic engineering tools, like CRISPR-Cas9, for particular research activities.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Why did the Pharmaceutical R&D Segment Dominate the Market in 2024?

In 2024, the pharmaceutical R&D segment captured the largest share of the organoids market. Along with the rising demand for tailored medicine, companies are bolstering advances in stem cell technology (like iPSCs), 3D bioprinting, and microfluidics. Besides this, pharmaceutical leaders are putting efforts to accelerate the use of AI and machine learning to assess the generation of vast data sets in organoid systems.

Although the precision medicine segment will expand fastest during 2025-2034. The globe is phenomenally moving towards customising treatments to individual patients based on their genetic makeup. Through the broader exploration of integrated multi-omics (transcriptomics, proteomics, metabolomics) with organoid models, researchers are acquiring detailed insights into drug metabolism and toxicity. Continuous expansion of biobanks, breakthroughs in microenvironmental modeling, are also impacting further developments in these treatments.

What are the Key Developments in the Organoids Market?

In October 2025, AMS Biotechnology (Amsbio) launched a new range of over 30 independently created and produced organoid culture-related cytokines for researchers working with stem cells and induced pluripotent stem cells (iPSCs).
In June 2025, iXCells Biotechnologies launched the iPSCore platform for developing highly characterized iPSC-derived human cell models.
In April 2025, Turbine introduced the world’s first virtual lab using cell simulations.
In January 2025, Inventia Life Science unveiled RASTRUM Allegro to transform high-throughput 3D cell culture for drug discovery and disease research.

Browse More Insights of Towards Healthcare:

The global kidney organ-on-a-chip market was valued at USD 192 million in 2024, increased to USD 232.84 million in 2025, and is projected to reach approximately USD 1,314.52 million by 2034, expanding at a CAGR of 21.27% between 2025 and 2034.

The global iPSC-based platforms market is witnessing strong growth momentum and is anticipated to generate substantial revenue over the forecast period from 2025 to 2034, potentially reaching several hundred million dollars as demand accelerates.

The global infant formula market was valued at USD 82.4 billion in 2024, grew to USD 90.27 billion in 2025, and is expected to reach around USD 207.19 billion by 2034, exhibiting a CAGR of 9.55% between 2025 and 2034.

The global organ transplant immunosuppressant drugs market was valued at USD 5.55 billion in 2024, increased to USD 5.81 billion in 2025, and is projected to reach about USD 8.82 billion by 2034, growing at a CAGR of 4.74% between 2025 and 2034.

The global organ-on-a-chip market was valued at USD 159.48 million in 2024, is expected to rise to USD 215.53 million in 2025, and further reach approximately USD 3,242.34 million by 2034, recording a robust CAGR of 35.15% between 2024 and 2034.

The organoids and spheroids market is forecast to expand from USD 1,220.92 million in 2025 to USD 7,942.56 million by 2034, reflecting a CAGR of 23.13% during the same period.

The perfusion systems market was valued at USD 1.15 billion in 2023 and is projected to grow to USD 1.94 billion by 2034, advancing at a CAGR of 4.85% between 2024 and 2034.

The global scaffold technology market was estimated at USD 2.05 billion in 2023 and is expected to reach USD 8.58 billion by 2034, growing steadily at a CAGR of 13.9% from 2024 to 2034.

Organoids Market Key Players List

Hub Organoids
Definigen
Cellesce Ltd.
Thermo Fisher
Sanofi
NeyroblastGX
StemCell Technologies
Organoid Therapeutics
Bio-Techne
Thermo Fisher Scientific Inc.
3Dnamics Inc.
PeproTech Inc.
Molecular Devices, LLC
Merck KGaA
Corning Inc.
CN Bio Innovations Ltd.

Segments Covered in the Report

By Type

Stem Cell Source
Tumour Cell Source

By Application

Pharmaceutical R & D
Precision Medicine
Academic & Research Institute

By Region

North America
- U.S.
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/5265

Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.